Shire to acquire Dyax for $5.9B

Monday, November 2, 2015

Dublin-based Shire has announced it will acquire Dyax for $37.30 in cash per Dyax share, for aggregate upfront consideration of about $5.9 billion. Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4 in cash per Dyax share upon approval of DX-2930 in HAE, representing a potential additional $646 million in aggregate contingent consideration.

[Read More]

Shire acquires Foresight Biotherapeutics for $300M

Wednesday, August 5, 2015

Shire has acquired New York-based, privately held Foresight Biotherapeutics for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a therapy in late-stage development for the treatment of infectious conjunctivitis, an ocular surface condition commonly referred to as pink eye. This acquisition further strengthens Shire’s late-stage pipeline, has a clear strategic fit with lifitegrast, which is in late-stage development for treatment of dry-eye disease, and further demonstrates Shire’s commitment to building a leadership position in ophthalmics.

[Read More]

Halozyme names Laurie Stelzer CFO

Monday, June 8, 2015

Halozyme Therapeutics, an oncology biotech company headquartered in San Diego, has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume chief financial officer  duties on June 15 and will work with Ramsay through a transition period.

[Read More]

TransCelerate Biopharma turns three

Monday, June 1, 2015

The name alone excites many in clinical research. It’s the first—or so far best promoted—consortium consisting only of high-level people from big biopharmaceutical companies, each vowing to be deeply “pre-competitive” with one another while trying to rework some of the redundant and wasteful practices endemic to clinical research.

[Read More]

Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Monday, May 4, 2015

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

[Read More]

FDA grants Priority Review to lifitegrast NDA for dry eye disease in adults

Thursday, April 9, 2015

The FDA has accepted for filing Shire‘s NDA for lifitegrast and granted a Priority Review designation. Lifitegrast is an investigational treatment for dry eye disease in adults and, if approved, has the potential to be the first treatment indicated to address both signs and symptoms of the disease. The FDA is expected to provide a decision on October 25, based on the Prescription Drug User Fee Act V action date.

[Read More]